Centerpoint Advisors, LLC Halozyme Therapeutics, Inc. Transaction History
Centerpoint Advisors, LLC
- $286 Million
- Q4 2024
A detailed history of Centerpoint Advisors, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Centerpoint Advisors, LLC holds 550 shares of HALO stock, worth $35,838. This represents 0.01% of its overall portfolio holdings.
Number of Shares
550
Previous 550
-0.0%
Holding current value
$35,838
Previous $31,000
16.13%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
550Shares Held
124MCall Options Held
668KPut Options Held
259K-
Black Rock Inc. New York, NY17.6MShares$1.15 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$865 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$468 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$272 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$225 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.08B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...